Applied Stock Analysis

APLT -  USA Stock  

USD 22.44  1.25  5.28%

The newest price gain of Applied Therapeutics could raise concerns from private investors as the firm it trading at a share price of 22.44 on very low momentum in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 28.04. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Applied Therapeutics partners.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Applied Therapeutics stock analysis report makes it easy to digest most publicly released information about Applied Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Applied stock analysis module also helps to analyze the Applied Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Applied Stock Analysis Notes

About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.28. Applied Therapeutics had not issued any dividends in recent years. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Applied Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. For more info on Applied Therapeutics please contact the company at 212 220 9226 or go to http://www.appliedtherapeutics.com.

Applied Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Applied Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Applied Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Applied Therapeutics is way too risky over 90 days horizon
Applied Therapeutics appears to be risky and price may revert if volatility continues
Applied Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (93.96 M).
Applied Therapeutics currently holds about 96.83 M in cash with (78.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Applied Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 62.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.equities.com: Applied Therapeutics Inc gains 3.2690 percent for June 17 - Equities.com

Applied Therapeutics Upcoming and Recent Events

Earnings reports are used by Applied Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Applied Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of August 2021
Next Earnings Report11th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Applied Largest EPS Surprises

Earnings surprises can significantly impact Applied Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-08-12
2019-06-30-0.4289-0.6-0.171139 
2019-11-13
2019-09-30-0.4417-0.63-0.188342 
2020-05-11
2020-03-31-0.8367-0.590.246729 
View All Earnings Estimates

Applied Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Applied Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Applied Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Applied Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
4th of June 2021
Submission of Matters to a Vote of Security Holders
View
11th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of April 2021
Unclassified Corporate Event
View
18th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
17th of February 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
16th of February 2021
Unclassified Corporate Event
View
12th of February 2021
Unclassified Corporate Event
View
8th of February 2021
Unclassified Corporate Event
View

Applied Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Applied Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Applied Therapeutics backward and forwards among themselves. Applied Therapeutics' institutional investor refers to the entity that pools money to purchase Applied Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares2.5 M47.5 M
Orbimed Advisors LlcCommon Shares2.3 M42.3 M
Blackrock IncCommon Shares1.2 M22.6 M
Alkeon Capital Management LlcCommon SharesM19.5 M
Knoll Capital Management LlcCommon SharesM19.2 M
Vanguard Group IncCommon Shares834.2 K15.6 M
Franklin Resources IncCommon Shares749 K14 M
Note, although Applied Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Applied Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 614.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Applied Therapeutics's market, we take the total number of its shares issued and multiply it by Applied Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Applied Profitablity

Applied Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Applied Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Applied Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Applied Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Applied Therapeutics' profitability requires more research than a typical breakdown of Applied Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.69) (0.74) 
Return on Average Equity(0.80) (0.86) 
Return on Invested Capital(2.02) (2.08) 

Management Efficiency

The entity has return on total asset (ROA) of (77.23) % which means that it has lost $77.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (164.06) %, meaning that it created substantial loss on money invested by shareholders. Applied Therapeutics management efficiency ratios could be used to measure how well applied therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.74 in 2021. Return on Average Equity is likely to drop to -0.86 in 2021. Liabilities Non Current is likely to gain to about 1.3 M in 2021, whereas Total Liabilities is likely to drop slightly above 18.2 M in 2021.
Last ReportedProjected for 2021
Book Value per Share 3.73  4.03 
Enterprise Value over EBIT(5.00) (5.39) 
Enterprise Value over EBITDA(4.82) (5.20) 
Price to Book Value 6.04  7.47 
Tangible Assets Book Value per Share 4.76  4.36 
Enterprise Value448.1 M425.8 M
Tangible Asset Value104.5 M112.8 M

Technical Drivers

As of the 19th of June, Applied Therapeutics shows the Downside Deviation of 10.91, risk adjusted performance of 0.128, and Mean Deviation of 7.34. Applied Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Applied Therapeutics, which can be compared to its rivals. Please confirm Applied Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Applied Therapeutics is priced correctly, providing market reflects its regular price of 22.44 per share. Given that Applied Therapeutics has jensen alpha of 1.79, we suggest you to validate Applied Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Applied Therapeutics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of five hundred ten. The Mid-point over period is an average of Applied Therapeutics highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Applied Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Applied Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Applied Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Applied Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Silberstein Charles over a week ago via Macroaxis 
Sale by Silberstein Charles of 5047 shares of Applied Therapeutics
Perfetti Riccardo over a week ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 460 shares of Applied Therapeutics subject to Rule 16b-3
Kanter Stacy J over two weeks ago via Macroaxis 
Acquisition by Kanter Stacy J of 16500 shares of Applied Therapeutics subject to Rule 16b-3
Hansard Adam over two weeks ago via Macroaxis 
Sale by Hansard Adam of 2894 shares of Applied Therapeutics
Perfetti Riccardo over three weeks ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 460 shares of Applied Therapeutics subject to Rule 16b-3
Mahadevan Chids over a month ago via Macroaxis 
Acquisition by Mahadevan Chids of 13412 shares of Applied Therapeutics subject to Rule 16b-3
Perfetti Riccardo over a month ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 200 shares of Applied Therapeutics subject to Rule 16b-3
Perfetti Riccardo over a month ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 400 shares of Applied Therapeutics subject to Rule 16b-3
Perfetti Riccardo over two months ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 200 shares of Applied Therapeutics subject to Rule 16b-3
Perfetti Riccardo over two months ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 460 shares of Applied Therapeutics subject to Rule 16b-3
Perfetti Riccardo over three months ago via Macroaxis 
Exercise or conversion by Perfetti Riccardo of 465 shares of Applied Therapeutics subject to Rule 16b-3
Kanter Stacy J over three months ago via Macroaxis 
Purchase by Kanter Stacy J of 6500 shares of Applied Therapeutics

Applied Therapeutics Technical and Predictive Indicators

Applied Therapeutics Forecast Models

Applied Therapeutics time-series forecasting models is one of many Applied Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Applied Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Applied Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Applied Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Applied shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Applied Therapeutics. By using and applying Applied Stock analysis, traders can create a robust methodology for identifying Applied entry and exit points for their positions.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Applied Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.

Current Applied Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Applied analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Applied analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
60.0Strong Buy2Odds
Applied Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Applied analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Applied stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Applied Therapeutics, talking to its executives and customers, or listening to Applied conference calls.
Applied Analyst Advice Details

Applied Stock Analysis Indicators

Applied Therapeutics stock analysis indicators help investors evaluate how Applied Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Applied Therapeutics shares will generate the highest return on investment. By understating and applying Applied Therapeutics stock analysis, traders can identify Applied Therapeutics position entry and exit signals to maximize returns.
Shares Percent Shares Out5.87%
Quick Ratio4.58
Fifty Two Week Low13.58
Short Percent Of Float8.69%
Forward Price Earnings-4.96
Float Shares15.63M
Fifty Two Week High49.88
Shares Short Prior Month1.51M
Average Daily Volume Last 10 Day76.2k
Average Daily Volume In Three Month91.84k
Fifty Day Average18.28
Two Hundred Day Average20.29
Please continue to Trending Equities. Note that the Applied Therapeutics information on this page should be used as a complementary analysis to other Applied Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Applied Therapeutics Stock analysis

When running Applied Therapeutics price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for activelly-traded equities including funds and ETFs from over 30 global markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
The market value of Applied Therapeutics is measured differently than its book value, which is the value of Applied that is recorded on the company's balance sheet. Investors also form their own opinion of Applied Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Applied Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Applied Therapeutics' market value can be influenced by many factors that don't directly affect Applied Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Applied Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Applied Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Applied Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.